×

AstraZeneca late to the party on immunotherapy cancer treatment: Analyst

4:16 AM ET Thu, 27 July 2017

Mick Cooper, analyst Trinity Delta, discusses pharma giant AstraZeneca following news that an immunotherapy drug it was trialing has been less successful than was hoped.